Company news
Personalis, Inc. news in 2025
Personalis, Inc.'s news releases, calls and decks from 2025, newest first.
Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors
December 16, 2025
New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer
December 10, 2025
Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 17, 2025
Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer
November 9, 2025
Personalis Reports Third Quarter 2025 Financial Results
November 3, 2025
Personalis to Announce Third Quarter 2025 Financial Results
October 20, 2025
Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing
October 15, 2025
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 14, 2025
CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test
September 9, 2025
Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing
September 2, 2025
Personalis to Participate in Upcoming Investor Conferences
August 26, 2025
Personalis Reports Second Quarter 2025 Financial Results
August 4, 2025
Personalis to Announce Second Quarter 2025 Financial Results
July 21, 2025
Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients
July 8, 2025
Personalis’ NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO
June 2, 2025
New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse
June 1, 2025
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection
May 21, 2025
Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference
May 13, 2025
Personalis Reports First Quarter 2025 Financial Results
May 5, 2025
Personalis’ NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study
April 27, 2025
Personalis to Announce First Quarter 2025 Financial Results
April 21, 2025
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection
April 21, 2025
Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference
March 25, 2025
New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection
March 2, 2025
Personalis Reports Fourth Quarter and Full Year 2024 Financial Results
February 26, 2025
Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference
February 17, 2025
Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results
February 12, 2025
Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
January 27, 2025
Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue
January 6, 2025
Calls in 2025
Decks in 2025
- Q1 2025 Earnings Presentation
Earnings · 20 slides · May 6, 2025